加载中
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$0.6039
+US$0.0142 · +2.41%
前收盘价
US$0.6039
+US$0.0142 · +2.41%
盘前
US$0.60
−US$0.0039 · -0.65%
10月13日 6:02 ET
盘中时间采用ET。市场数据可能有所延迟。
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
日内区间
当前US$0.6039
52周区间
当前US$0.6039
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.08亿 USD | 9004.9万 USD | 7019.3万 USD | 3705.4万 USD | 2223.9万 USD |
| 销货成本 | 4343.4万 USD | 3490.8万 USD | 2626.4万 USD | 1783.5万 USD | 1167.5万 USD |
| 毛利 | 6444.1万 USD | 5514.1万 USD | 4392.9万 USD | 1921.9万 USD | 1056.4万 USD |
| 研究与开发 | 1035万 USD | 1055.2万 USD | 637.6万 USD | 755.7万 USD | 558.9万 USD |
| 销售、一般及管理费用 | 6675.1万 USD | 6139.6万 USD | 5992.5万 USD | 5012.1万 USD | 3021.7万 USD |
| 营业费用 | 7984.2万 USD | 7986.3万 USD | 7125.6万 USD | 5711.9万 USD | 3740.5万 USD |
| 利息收入 | 150.2万 USD | 107.8万 USD | 108.8万 USD | 12.5万 USD | 1.1万 USD |
| 利息支出 | 1216.1万 USD | 762.9万 USD | 577.2万 USD | 274.3万 USD | 187.5万 USD |
| 折旧和摊销 | 920.8万 USD | 803.9万 USD | 685.9万 USD | 490.9万 USD | 303.6万 USD |
| 营业利润 | −1540.1万 USD | −2472.2万 USD | −2732.7万 USD | −3790万 USD | −2684.1万 USD |
| 净利润 | −3351.9万 USD | −3806.9万 USD | −4310万 USD | −4404.4万 USD | −2900.2万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$2.50
上涨空间 313.98%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年11月14日 | 1:10 | — | — |
已生效 2023年11月14日
1:10
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
